Jeffrey Shuman
About Jeffrey Shuman
Independent director of Sidus Space (age 70) with 40+ years across military and global corporates; appointed to the Board in July 2024 and designated Lead Independent Director in February 2025 . Former CHRO at Harris Corporation (now L3Harris) and Quest Diagnostics, with earlier senior roles in Operations, General Management and HR at Northrop Grumman, Honeywell, and Avon; BA from The Citadel and executive programs at Michigan, Harvard Business School, UVA Darden, Wharton, and Cornell; multiple industry HR awards . Board biography lists advisory roles at Garner Health, The Citadel School of Business and Psychology Department, and CIELO Talent (emeritus), underscoring human capital and governance expertise .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Harris Corporation (now L3Harris) | Chief Human Resources Officer | Not disclosed | Led HR during “profound cultural and operational progress” |
| Quest Diagnostics | Chief Human Resources Officer | Not disclosed | HR leadership through operational change |
| Northrop Grumman; Honeywell; Avon | Senior executive roles (Operations, GM, HR) | Not disclosed | Cross-functional leadership across diversified industries |
| U.S. Army (Medical Services Corps) | Officer | Not disclosed | Military leadership foundation |
External Roles
| Organization | Role | Tenure |
|---|---|---|
| Garner Health | Advisory Board member | Not disclosed |
| The Citadel School of Business | Advisory Board member | Not disclosed |
| The Citadel Psychology Department | Advisory Board member | Not disclosed |
| CIELO Talent | Advisory Board emeritus | Not disclosed |
Board Governance
- Lead Independent Director since February 2025; role “closely aligned with the role of an independent chairperson” .
- Independence: Board determined Shuman (and majority of directors) are independent under Nasdaq and SEC rules .
- Committee memberships:
- Audit Committee member; Dana Kilborne (Chair). Audit met 7 times in FY2024 .
- Compensation Committee Chair; members Oliver, Riera, Coffey. Compensation met 0 times in FY2024 .
- Not on Nominating & Governance Committee .
- Attendance: All directors attended every Board meeting in FY2024 (six meetings) .
- Board size and nominees: Six nominees including Shuman (age 70) for 2025 Annual Meeting .
Fixed Compensation
| Year | Fees Earned or Paid in Cash ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|
| 2024 | 23,889 | 10,000 | 33,889 |
Notes:
- Shuman joined as director in July 2024; amounts reflect partial-year service .
Performance Compensation
| Component | Terms | Metrics |
|---|---|---|
| Annual equity grant (director) | Not disclosed | Not disclosed |
| Performance-based awards | Not disclosed | Not disclosed |
Other Directorships & Interlocks
| Category | Details |
|---|---|
| Current public company boards | None disclosed in the proxy |
| Private/advisory roles | Advisory boards at Garner Health, The Citadel School of Business and Psychology; CIELO Talent (emeritus) |
| Interlocks/potential conflicts | No related-party relationships disclosed involving Shuman; Company’s related-party transactions are concentrated with CEO’s entity (CTC) rather than Shuman |
Expertise & Qualifications
- Human capital leadership: CHRO at L3Harris and Quest; executive roles across operations and HR .
- Education: BA from The Citadel; executive programs at Michigan, Harvard Business School, UVA Darden, Wharton, Cornell .
- Recognition: Stevie Award “Best Human Resources Executive”; HR Executive Magazine “HR Executive of the Year” 2011 .
- Skills matrix: Governance, Operations, Industry Knowledge, and Risk Management marked for Shuman in director skills summary .
Equity Ownership
| Holder | Class A Shares Beneficially Owned | Class B Shares Beneficially Owned | % of Common Stock |
|---|---|---|---|
| Jeffrey Shuman | 0 | 0 | 0% |
Notes:
- Beneficial ownership table shows no Class A or Class B holdings for Shuman as of record date (April 28, 2025) .
- No pledging, hedging, options or RSUs disclosed for Shuman; equity plan capacity exists, but director grants not itemized .
Governance Assessment
-
Positives:
- Elevation to Lead Independent Director in Feb 2025 strengthens independent oversight with an LID mandate aligned to independent chair standards .
- Independent status and dual committee roles (Audit member; Compensation Chair) add governance ballast for controls and pay oversight .
- 100% Board attendance in FY2024 signals engagement; Audit Committee met robustly (7x) amid auditor transition and re-audit context .
-
Watch items / Red flags:
- Compensation Committee held zero meetings in FY2024; while Shuman’s chairmanship began later, committee cadence should normalize to ensure effective pay oversight (particularly after equity plan expansion in 2024) .
- Company-level related-party exposure (leases, services, advances) with CEO’s entity (Craig Technical Consulting) persists; demands vigilant Audit and LID oversight to mitigate perceived conflicts and ensure arm’s-length terms .
- Prior auditor change and re-audit tied to PCAOB/SEC sanctions of former auditor underscores control environment risk; continued tight audit oversight is warranted .
-
Alignment:
- Shuman’s director compensation appears primarily cash retainer; no disclosed equity ownership or grants, implying limited “skin-in-the-game” alignment at present. As LID and Comp Chair, adopting a standard annual equity component for directors would strengthen alignment with shareholder outcomes .
Discrepancy note: Proxy biography lists Shuman’s appointment as July 2025, while the compensation footnote and beneficial ownership context indicate July 2024. Company should correct record continuity in future disclosures .